Insuline Novorapid 300iu

INSULIN NOVORAPID 300 IU

Manufacturer: Novo 
Package: 1 pre-filled FlexPen, 3 mL
Common Names: NovoRapid, NovoRapid FlexPen, Insulin Aspart, Insulin Aspartate, Aspart Insulin

Info: NovoRapid 300 IU contains insulin aspart, a rapid-acting recombinant human insulin analogue used to help control blood glucose levels in patients with diabetes mellitus who require insulin therapy. Insulin aspart acts rapidly after subcutaneous administration and is designed to provide mealtime insulin coverage. It works by increasing glucose uptake into insulin-sensitive tissues and reducing glucose production by the liver.

Effects

Blood Glucose Control: Insulin aspart helps lower blood glucose by facilitating the uptake of glucose into muscle and adipose tissue and reducing hepatic glucose production.

Mealtime Insulin Coverage: NovoRapid is a rapid-acting insulin analogue intended to control the rise in blood glucose associated with meals. Its rapid onset makes it suitable for use around mealtimes as part of an individualized insulin treatment regimen.

Dosage Range and Duration of Use

NovoRapid is supplied as a 100 IU/mL solution, with each 3 mL pre-filled pen containing 300 IU of insulin aspart. The appropriate dose and timing must be determined individually by a qualified healthcare professional based on blood glucose levels, insulin requirements, dietary intake, previous treatment, and other clinical factors. NovoRapid is generally administered subcutaneously immediately before a meal and may be used in combination with a longer-acting or intermediate-acting insulin when basal insulin coverage is required.  

Side Effects

The most important adverse effect associated with insulin therapy is hypoglycemia, which can occur when the insulin dose exceeds the body's requirements. Symptoms may include sweating, shakiness, hunger, dizziness, confusion, weakness, blurred vision, or changes in consciousness. Other possible effects include injection-site reactions, lipodystrophy, localized cutaneous amyloidosis, allergic reactions, temporary visual disturbances, and changes in potassium levels.

Post-Cycle Therapy

NovoRapid contains insulin aspart and is not an anabolic steroid, androgenic compound, or testosterone-suppressing agent. Conventional post-cycle therapy (PCT), as used following anabolic steroid cycles, is therefore not applicable. NovoRapid is a prescription insulin medication intended for blood glucose management and should be used according to appropriate medical guidance.

Storage

Keep NovoRapid in accordance with the manufacturer's storage recommendations. Protect the insulin from excessive heat, direct sunlight, and freezing. Keep the product out of the reach of children. Before use, inspect the solution and do not use the pen if the insulin appears abnormal, discolored, or contains particles, or if the device is damaged.